Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS)
Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation
Sponsor: Bayer
This observational or N/A phase trial investigates Atrial Fibrillation and is currently completed. Bayer leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2022 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Sep 2022 [monthly]
Completed
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Multiple Locations, Austria , Multiple Locations, Belgium , Multiple Locations, Canada , Multiple Locations, Czechia , Multiple Locations, Denmark , Multiple Locations, France , Multiple Locations, Germany , Multiple Locations, Hungary , Multiple Locations, Ireland , Multiple Locations, Israel and 11 more locations